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The EMLs are collected and compared from 31 provinces; the indictors of EDP are
evaluated before and after implementation. RESULTS: Although national EDL only
contains 307 essential medicines, the number of added EMs in provincial EDL are
various from 64 through 455. The zero-markup policy of EDs conducted in public
grass-roots health facilities (urban community health centers and rural township
hospitals) have reached to 98.8%. More than 95% EDs can be reimbursement by
medical insurance schemes. The average percentage of price cutting was 25%-50%
after tender bidding and purchasing. Quality assurance and sufficient provision of
ED became a problem. The number of essential medicines is still not meet the
needs of outpatients so that patients flow back to the secondary and tertiary hos-
pitals, the financial subsidies from government usually are not supported timely.
Along with the expansion of EDP in village health posts and hospitals, how to
incentive and maintain the income level of health professionals have to be
considered. CONCLUSIONS: To promote the EMP, the adjustment of EDL is required in
2012. The criteria of selectiononessentialmedicines inprovincial level shouldbeunified.
The implementationof EMPwill notbe successful invillageandurbanhospital leveluntil
solving the problemof remuneration and payment system in health settings.
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OBJECTIVES: To compare health expenditure as total % of GDP, per capita PPP and
inUS dollars aswell as total drug expenditurewith top tenATC groupswith highest
expenditure in 2009 and 2010 in Bosnia & Herzegovina (B&H) and Croatia (CRO).
METHODS: Research was based on data published in latest official annual reports
from two national Drug Agencies, from B&H and CRO, and official reports from The
World Bank. Analysis was performed for all drugs and top ten ATC groups were
identified and compared in both countries for two years – 2009 and 2010. RESULTS:
The Health expenditure; total (% of GDP) in B&H was 10.94 in 2009 (10.31 in 2008),
CRO - 7.83 in 2009 (7.83 in 2008). In 2009, total drug expenditure in B&H was 238.8
mil EUR compared to 269 in 2010 (increase of 11,23%), while in CRO in 2009 it was
625.6 mil EUR compared to 664.5 in 2010 (increase of 5,85%). Top 10 ATC 1st level
drug groups with highest expenditure in both countries in 2009 and 2010 were
rather similar but on ATC 2nd level we observed significant differences in the share
of relevant ATC groups with leading C09, J01 and L01 for 2009 and C09, J01 and A10
for 2010 in B&H. Leading groups in CRO for 2009 were L01, J01 and C09, and for 2010
J01, C09 and L01. No drugs from C10 group were present in top ten ATC 2nd level in
B&H as well as R03 in 2009 and 2010 unlike the CRO. CONCLUSIONS: CRO has a
stable total health expenditure and universal health care system with twice
smaller increase in total drug expenditure compared to B&H. B&H is a country with
decentralized health care system including drug politics and positive reimburse-
ment drug lists which need to be equalized.
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OBJECTIVES: As part of the Affordable Care Act of 2010 (ACA), smoking cessation
medications (SCMs) including bupropion, varenicline, and nicotine-replacement
drugs, will be provided at no cost to people with health insurance. However, the
scope of the potential impact of this policy was unclear. This study explored which
populations would benefit from this mandate. METHODS: A retrospective cross-
sectional study using the nationally representativeMedical Expenditure Panel Sur-
vey 2009 was conducted. Adults who currently smoke, advised by doctors to quit
smoking, or diagnosed tobacco-use disorderswere extracted for analysis (weighted
N40,095,913). Chi-square tests and one-way ANOVAswere conducted to examine
the heterogeneity in SCM use and related out-of-pocket expenses with respect to
socio-demographic factors. A logistic regression was performed to examine the
associations between socio-demographic factors and SCM use. All analyses were
weighted based on complex survey design. RESULTS: Of the 40,095,913 smokers,
only 3.1% of them used SCMs in 2009, whereas 52.1% were advised by doctors to
quit smoking. Chi-square analyses revealed significant differences in SCM use
based on race/ethnicity, relationship status, health insurance status, HMO status,
perceived mental health status, and comorbid depressive/bipolar disorders (all
p0.001). Uses in buprorion and varenicline also varied with health insurance sta-
tus (both p0.05). There were significant differences in out-of-pocket expense for
SCMs between smokerswith different insurance status, with the uninsured paying
the highest out-of-pocket price (p0.001). The logistic regression revealed that
non-Hispanic blacks were less likely to take SCMs compared with Hispanics
(OR0.30, p0.01). CONCLUSIONS: Cost is a substantial barrier to SCM use among
smokers.Once thisbarrier is liftedwith theACA,manysmokerswhodonotcurrentlyuse
SCMsare likely touseSCMsunless theyhaveunfavorableattitudes towardsSCMuseand
smokerswho currently use SCMsmight switch tomore effective but expensive SCMs.
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OBJECTIVES:This paper proposes, based on a theoretical framework for estimating
demand functions under uncertainty, to highlight the importance of including
economic variables of market operation and actors strategic organization in the
design of regulations on the pharmaceutical sector. They can contribute beyond
the value of pharmacological and clinical tools in the specification of standards
within a framework of evidence-basedmedicine and the dynamic analysis of cost-
effectiveness in decisionmaking froman institution of sectoral superintendence of
social insurance. METHODS: With a database of 9147 and 27647 comments on
covered population prescriptions by social security in Argentina, we analyze the
therapeutic groups of hypertensive and lipid lowering, respectively, by the classical
least squares estimation and logistic models for each product. RESULTS: The data
provide consistent messages about the presence of differentiation mechanisms
that overshadow the traditional negative relationship between price and sales. In
particular, the interaction between brand and drugs, which can be extended to
technological changes in a dynamic context, implies a complementary perspective
in designing the regulatory framework. CONCLUSIONS: The power of negotiation
and establishment of rules of producersmust be considered in eachparticular case,
to coordinate incentives to encourage rational behavior in prescribing, moving in a
pattern of more cost-effective.
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OBJECTIVES: There is a need as well as a demand for understanding the influences
that are changing the landscape in terms of pharma management in the Middle
Eastern region. This research is focussed on theUAE, one of the pioneers of a formal
pharmaceutical assessment, to understand drivers of reform and implications.
METHODS: Initial desk research was conducted to understand trends in reim-
bursement decisions and pricing of drugs. This was followed by in-depth inter-
views with 4 stakeholders in the Emirati system to understand historical influ-
ences, current trends, drivers for decision making and future changes expected.
These data were analysed qualitatively to produce results. RESULTS: All respon-
dents (n4) thought of the UAE as one of the regional pioneers of adopting West-
ern-style pharmaceuticals management systems. The imminent introduction of
US-style PBMs is likely to be a major step in this direction. In addition, the govern-
ment are working on the development of a centralised patient record that will
include GCC/ME countries. This will help providers access patient history easily,
prescribe more efficiently, avoid medication errors amongst other things. The in-
creasing cost of drugs associated with the universal health insurance system (dou-
bled national fund for the purchase of medicines this year) along with the high use
of imported drugs was thought to be the most important driver for reform by
majority of the respondents (n3). All respondents were aware of the regional
influence of the UAE reforms. CONCLUSIONS: P&R of pharmaceuticals is expected
to move from a chaotic system to a more transparent, regulated one that requires
submission of PE evaluations and clinical evidence. The MOH has already started
developing a patient registry to assess validity claims from manufacturers. In a
country where most of the drugs are imported due to lack of local manufacturing
capabilities, it will become an increasingly important market for international
manufacturers.
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OBJECTIVES: To analyze the consumption of medicines for the treatment of peptic
ulcer and gastroesophageal reflux disease (ATC subgroup A02B) in Serbia in corre-
lation with Norway. METHODS: Data on drug utilization in 2009 have been pro-
vided by the annual reports of the Agency for Drugs and Medical Devices of the
Republic of Serbia and the Norwegian Institute for Public Health. The results were
expressed as the number of defined daily doses per 1000 inhabitants per day (DDD/
TID). A qualitative analysis was carried out according to the Drug Utilization 90%
(DU90%) approach. RESULTS: The overall consumption of medicines for peptic
ulcer and gastroesophageal reflux disease was twofold lower in Serbia than in
Norway (21.16 DDD/TID vs. 42.31 DDD/TID). Histamine H2-receptor antagonists
accounted for 73% (15.43 DDD/TID) of A02B medicines consumption in Serbia ver-
sus 14% (6.11 DDD/TID) in Norway. Whereas in Serbia, proton pump inhibitors
participatedwith 26.26% (5.56 DDD/TID)within A02B subgoup utilization, the share
of these medicines in Norway was 84.42% i.e. 35.72 DDD/TID. Within DU90% seg-
ment, 4 (of 7) medicines have been found in Serbia and 5 (of 10) in Norway. The
most commonly used medicines within A02B subgroup in Serbia were ranitidine
(60.9%, 12.9 DDD/TID), omeprazole (12.7%, 2.69 DDD/TID), famotidine (11.9%, 2.53
DDD/TID), and pantoprazole (7.7%, 1.63 DDD/TID), whilst in Norway were esome-
prazole (33.9%, 14.34 DDD/TID) followed by pantoprazole (19.3%, 8.18 DDD/TID),
omeprazole (15.7%, 6.67 DDD/TID), lansoprazole (15.4%, 6.53 DDD/TID) and raniti-
dine (10.6%, 4.51 DDD/TID).CONCLUSIONS: Besides the quantity, the pattern of use
of medicines for peptic ulcer and gastroesophageal reflux disease showed differ-
ences between observed countries. Differences in prescription regulations, price
and reimbursementmost likely influenced the type and amount of medicines con-
sumed.
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